Dr. Lim is a Consultant Neurologist and Professor at the University of Malaya, Kuala Lumpur, where he runs a very busy government clinic and private practice seeing many patients (around 70 every week) with Parkinson’s disease (PD) and other Movement Disorders, including complicated cases requiring advanced treatments such as deep brain stimulation.

Dr. Lim earned his medical and research doctorate degrees from the University of Melbourne and was admitted to Fellowship of the Royal Australasian College of Physicians after completing advanced training in adult Internal Medicine and Neurology in Melbourne. Dr. Lim trained in general neurology and subspecialized in Parkinson’s & Movement Disorders, at world-renowned centres in Melbourne and Toronto (the latter supported by the Edmond J. Safra Fellowship, under Prof. Anthony Lang). He has published widely in the field of Movement Disorders (Parkinson's as well as a variety of rarer movement disorders), with approx. 150 peer-reviewed journal papers and book chapters, including first-author publications in Lancet Neurology, Archives of Neurology/JAMA Neurology, Movement Disorders, etc. and co-authorship in journals such as Nature Genetics, Nature Reviews Neurology, Annals of Neurology, and Brain (approx. 10K citations, h-index 44). He is on several Editorial Boards including Neurotorium, and is an Associate Editor for Science Advances and Neurology Asia.

Dr. Lim is the current Chair of the Asian-Oceanian section of the International Parkinson & Movement Disorder Society (MDS), and serves on several MDS Committees/Task Forces (for Evidence-Based Medicine; Progressive Supranuclear Palsy; Movement Disorders in Asia; Palliative Care; etc.). He is a Steering Committee member, and Co-Lead of the Under-Represented Populations Working Group, of the Global Parkinson's Genetics Program (GP2). He is a holder and/or Reviewer of grants for PD-related funding organisations such as the Michael J. Fox Foundation (MJFF), and the United Kingdom's National Institute for Health and Care Research (NIHR) and Cure Parkinspn's Trust (CPT).

With a strong commitment to teaching/training, Dr. Lim has organized numerous teaching courses on Parkinson’s & Movement Disorders, and delivered and/or participated in >200 international-level lectures and expert panels (in the United States, Canada, United Kingdom, Germany, France, Australia, Japan, Singapore, China, India, South Korea, Hong Kong, Taiwan, Thailand, Indonesia, Philippines, Sri Lanka, Brunei, Myanmar, United Arab Emirates, Kyrgyzstan, Mongolia, etc.). These have often been under the auspices of the MDS, as MDS Visiting Professor, MDS Ambassador, or MDS Virtual Professor. As a versatile speaker with broad-ranging expertise, he has been invited to give numerous Plenary Lectures, including at the flagship MDS Annual Congress (Toronto 2011, Dublin 2012, Nice 2019, Philadelphia/Virtual 2020, Copenhagen 2023, Hawaii 2025) and at the World Parkinson's Congress (Kyoto 2019). He has provided movement disorder fellowship training to neurologists from multiple underserved countries, including Indonesia, Myanmar, Bangladesh, Kyrgyzstan, Uzbekistan, Pakistan, India, the Philippines, and Nigeria, often under the auspices of the MDS (Visiting Trainee Grants or Centre-to-Centre Programs).

Dr. Lim is a Medical Advisor to the Malaysian Parkinson’s Disease Association, and a founding member (and Immediate-Past Chair) of the Malaysian Movement Disorder Council. He was elected as a Fellow of the Malaysian Academy of Sciences in 2017. In recognition of his leadership in the Movement Disorders field, he was invited to be an Expert Panelist/Consultant to the World Health Organization (WHO) in 2020 to address global policy, implementation and research related to PD.

Dr. Lim's research interests are multi-dimensional, with a focus on the following areas: (i) PD (particularly genetics and genotype-phenotype correlations; evidence-based medicine/clinical trials; non-motor features including gastrointestinal aspects; comorbidities; patient-centred care; and rating scales/disease staging); (ii) Parkinson-plus syndromes and other miscellaneous/"orphan" movement disorders, including progressive supranuclear palsy (PSP).